Pfizer Reports New England Journal Of Medicine Publication On Group B Streptococcus (GBS) Maternal Vaccine Candidate
Portfolio Pulse from Benzinga Newsdesk
Pfizer has reported results from an ongoing Phase 2 study on its Group B Streptococcus (GBS) maternal vaccine candidate, GBS6. The study, published in the New England Journal of Medicine, showed that the vaccine was well-tolerated and generated robust maternal antibody responses that were efficiently transferred to infants. The safety profile was similar between the vaccine and placebo groups in both mothers and infants.
July 19, 2023 | 9:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's ongoing Phase 2 study on its GBS6 vaccine has shown promising results, which could potentially boost investor confidence in the company's vaccine development capabilities.
The positive results from the Phase 2 study of Pfizer's GBS6 vaccine indicate that the company's vaccine development is progressing well. This could potentially lead to increased investor confidence in the company, which could positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100